Targeting persistent HIV infection: Where and how, if possible?

HIV and AIDS Review

Volumn 10, Issue 1, 2011, Pages 1-8

  Wayengera, Misaki ^a  

^a MAKERERE UNIVERSITY   (Uganda)

Author keywords

Anatomic hide outs; Cellular reservoirs; Hiv sanctuaries; Towards an HIV cure

Indexed keywords

ACTIN; ANTIBODY CONJUGATE; ANTIRETROVIRUS AGENT; BRYOSTATIN; COFILIN; COMPLEMENT RECEPTOR; COMPLEMENT RECEPTOR 2; CYCLIN DEPENDENT KINASE 9; CYCLIN T1; CYTOTOXIC AGENT; ENZYME ACTIVATOR; HEXAMETHYLENEBISACETAMIDE; HISTONE DEACETYLASE; MACROPHAGE INFLAMMATORY PROTEIN 3BETA; MESSENGER RNA; METHYL CPG BINDING PROTEIN 2; MONOCLONAL ANTIBODY; NANOPARTICLE; NEUTRALIZING ANTIBODY; POSITIVE TRANSCRIPTION ELONGATION FACTOR B; PROSTATIN; PSEUDOMONAS EXOTOXIN; REV PROTEIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; RNA POLYMERASE II; SAQUINAVIR; SECONDARY LYMPHOID TISSUE CHEMOKINE; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIRUS DNA;

ADD ON THERAPY; ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; ASTROCYTE; CD4 LYMPHOCYTE COUNT; CD8+ T LYMPHOCYTE; CELL CYCLE REGULATION; CELL NUCLEUS; CELLULAR DISTRIBUTION; CYTOKINE RELEASE; DNA TRANSCRIPTION; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; EPIGENETICS; FOLLICULAR DENDRITIC CELL; GENE EXPRESSION; GENOME; GERMINAL CENTER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTESTINE LYMPHATIC TISSUE; LYMPHOCYTE ACTIVATION; MACROPHAGE; MEMORY T LYMPHOCYTE; MONOCYTE; NATURAL KILLER CELL; NONHUMAN; PERSISTENT HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PERSISTENT VIRUS INFECTION; PROTEIN DEPHOSPHORYLATION; PROVIRUS; REVIEW; STEM CELL TRANSPLANTATION; TRANSACTIVATION; TRANSCRIPTION INITIATION SITE; UNSPECIFIED SIDE EFFECT; UPREGULATION; VIRAL CLEARANCE; VIRION; VIRUS ATTACHMENT; VIRUS INHIBITION; VIRUS LATENCY; VIRUS REPLICATION; ZOONOSIS;

EID: 80053935044     PISSN: 17301270     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hivar.2011.01.002     Document Type: Review

References (71)

1. M. Wayengera, H. Kajumbula, W. Byarugaba, Harnessing pharmacogenomics to tackle resistance to the "nucleoside reverse transcriptase inhibitor" backbone of highly active antiretroviral therapy in resource limited settings, Open AIDS J. 2 (2008) 78-81.
2. L. Geeraert, G. Kraus, R.J. Pomerantz, Hide-and-seek: the challenge of viral persistence in HIV-1 infection, Annu. Rev. Med. 59 (2008) 487-501. (Pubitemid 351287951)
3. J.K. Wong, M. Hezareh, H.F. Günthard, D.V. Havlir, C.C. Ignacio, C.A. Spina, et al., Recovery of replication-competent HIV despite prolonged suppression of plasma viremia, Science 278 (5341) (1997) 1291-1295. (Pubitemid 27495741)
4. D.D. Richman, D.M. Margolis, M. Delaney, W.C. Greene, D. Hazuda, R.J. Pomerantz, The challenge of finding a cure for HIV infection, Science 323 (5919) (2009) 1304-1307.
5. World Health Organization & Joint United Nations Programmed on HIV/AIDS (UNAIDS). Progress on global access to HIV antiretroviral therapy: a report on "3 by 5" and beyond. World Health Organization, Joint United Nations Programme on HIV/AIDS (UNAIDS), Geneva, Switzerland. Available from: http://www.who.int/hiv/fullreport en highres.pdf (Internet: accessed December 12, 2007).
6. Office of Global AIDS Coordinator U.S. President's Emergency Plan for AIDS Relief. Making a difference: supporting antiretroviral treatment. Of.ce of Global AIDS Coordinator, Washington, DC. Available from: http://www.state.gov/ documents/organization/67502.pdf (Internet: accessed December 12, 2007).
7. A. Attaran, Adherence to HAART: Africans take medicines more faithfully than North Americans, PLoS Med. 4 (2) (2007) e83.
8. J.N. Blankson, D. Persaud, R.F. Siliciano, The challenge of viral reservoirs in HIV-1 infection, Annu. Rev. Med. 53 (2002) 557-593. (Pubitemid 34177896)
9. D.M.Margolis, Mechanisms of HIV latency: an emerging picture of complexity, Curr. HIV/AIDS Rep. 7 (1) (2010) 37-43.
10. P. Cannon, S.H. Kim, C. Ulich, S. Kim, Distinct mechanisms of HIV-1 latency in the two cell line models U1 and ACH-2, in: Int. Conf. AIDS, August 7-12, 1994, vol. 10, p. 104 (abstract no. PA0035).
11. D. Finzi, M. Hermankova, T. Pierson, L.M. Carruth, C. Buck, R.E. Chaisson, et al., Identi.cation of a reservoir for HIV-1 in patients on highly active antiretroviral therapy, Science 278 (1997) 1295-1300. (Pubitemid 27495742)
12. J.K. Wong, M. Hezareh, H.F. Günthard, D.V. Havlir, C.C. Ignacio, C.A. Spina, et al., Recovery of replication-competent HIV despite prolonged suppression of plasma viremia, Science 278 (1997) 1291-1295. (Pubitemid 27495741)
13. T.W. Chun, L. Carruth, D. Finzi, X. Shen, J.A. DiGiuseppe, H. Taylor, et al., Quantitation of latent tissue reservoirs and total body load in HIV-1 infection, Nature 387 (1997) 183-188. (Pubitemid 27209433)
14. T. Pierson, J. McArthur, R.F. Siliciano, Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy, Annu. Rev. Immunol. 18 (2000) 665-708. (Pubitemid 30365394)
15. J.B. Dinoso, S.A. Rabi, J.N. Blankson, L. Gama, J.L. Mankowski, R.F. Siliciano, et al., Asimian immunode.ciency virus-infected macaque model to study viral reservoirs that persist during highly active antiretroviral therapy, J. Virol. 83 (18) (2009) 9247-9257.
16. T.W. Chun, D. Finzi, J. Margolick, K. Chadwick, D. Schwartz, R.F. Siliciano, In vivo fate of HIV-1-infected T cells: quantitative analysis of the transition to stable latency, Nat. Med. 1 (12) (1995) 1284-1290.
17. M. Wayengera, On the general theory of the origins of retroviruses, Theor. Biol. Med. Model 7 (2010) 5.
18. + T-cells from HIV-1-infected individuals, PLoS Pathog. 6 (2) (2010) e1000781.
19. A. Onafuwa-Nuga, L.A. McNamara, K.L. Collins, Towards a cure for HIV: the identification and characterization of HIV reservoirs in optimally treated people, Cell Res. (2010) (Epub ahead of print): PMID-20877313.
20. S.E. Kauder, A. Bosque, A. Lindqvist, V. Planelles, E. Verdin, Epigenetic regulation of HIV-1 latency by cytosine methylation, PLoS Pathog. 5 (6) (2009) e1000495.
21. M. Barboric, B.M. Peterlin, A new paradigm in eukaryotic biology: HIV Tat and the control of transcriptional elongation, PLoS Biol. 3 (2005) e76.
22. E.Y. Shim, A.K. Walker, Y. Shi, T.K. Blackwell, CDK-9/cyclin T (P-TEFb) is required in two postinitiation pathways for transcription in the C. elegans embryo, Genes Dev. 16 (2001) 2135-2146.
23. D. Sharma, J. Bhattacharya, Evolutionary constraints acting on DDX3X protein potentially interferes with Rev-mediated nuclear export of HIV-1 RNA, PLoS ONE 5 (3) (2010) e9613.
24. R.J. Pomerantz, T. Seshamma, D. Trono, Efficient replication of human immunodeficiency virus type 1 requires a threshold level of Rev: potential implications for latency, J. Virol. 66 (1992) 1809-1813.
25. R.J. Pomerantz, D. Trono, M.B. Feinberg, D. Baltimore, Cells nonproductively infected with HIV-1 exhibit an aberrant pattern of viral RNA expression: a molecular model for latency, Cell 61 (1990) 1271-1276.
26. V. Yedavalli, C. Neuveut, Y.-H. Chi, L. Kleiman, K.-T. Jeang, Requirement of DDX3X DEAD Box RNA Helicase for HIV-1 Rev-RRE export function, Cell 119 (2004) 381-392. (Pubitemid 39423840)
27. M.A. Valencia-Sanchez, J. Liu, G.J. Hannon, R. Parker, Control of translation and mRNA degradation by miRNAs and siRNAs, Genes Dev. 20 (5) (2006) 515-524. (Pubitemid 43345317)
28. J. Huang, F. Wang, E. Argyris, K. Chen, Z. Liang, H. Tian, et al., Cellular microRNAs contribute to HIV-1 latency in resting primary CD4+ T lymphocytes, Nat. Med. 13 (10) (2007) 1241-1247. (Pubitemid 47530631)
29. G.J. Hannon, J.J. Rossi, Unlocking the potential of the human genome with RNA interference, Nature 431 (7006) (2004) 371-378. (Pubitemid 39265678)
30. A.M. Denli, B.B. Tops, R.H. Plasterk, R.F. Ketting, G.J. Hannon, Processing of primary microRNAs by the microprocessor complex, Nature 432 (7014) (2004) 231-235. (Pubitemid 39545854)
31. + T cells from human immunode.ciency virus type 1 (HIV-1)-infected individuals carry integrated HIV-1 genomes within actively transcribed host genes, J. Virol. 78 (12) (2004) 6122-6133.
32. L.S. Weinberger, T. Shenk, An HIV feedback resistor: auto-regulatory circuit deactivator and noise buffer, PLoS Biol. 5 (1) (2007) e9.
33. + T cells depends on chemokineinduced changes in the actin cytoskeleton, Proc. Natl. Acad. Sci. U.S.A. 107 (39) (2010) 16934-16939.
34. + T cells to HIV-1 infection: a novel model of HIV-1 latency, Blood 110 (13) (2007) 4161-4164.
35. R.P. Bucy, J.M. Kilby, C.A. Derdeyn, D. Horton, M. Sillers, K. Squires, et al., Tissue reservoirs of HIV in lymph node before and after HAART, in: Conf. Retrovir. Oppor. Infect. 5th 1998 Chic Ill, February 1-5, 1998; 5th, vol. 233 (abstract no. S17).
36. L. Kacani, H. Stoiber, C. Speth, Z. Bánki, K. Tenner-Racz, P. Racz, et al., Complement-dependent control of viral dynamics in pathogenesis of human immunode.ciency virus and simian immunode.ciency virus infection, Mol. Immunol. 38 (2-3) (2001) 241-247. (Pubitemid 32786781)
37. S. Doepper, L. Kacani, B. Falkensammer, M.P. Dierich, H. Stoiber, Complement receptors in HIV infection, Curr. Mol. Med. 2 (8) (2002) 703-711. (Pubitemid 35385970)
38. J. Ho, S. Moir, L. Kulik, A. Malaspina, E.T. Donoghue, N.J. Miller, et al., Role for CD21 in the establishment of an extracellular HIV reservoir in lymphoid tissues, J. Immunol. 178 (11) (2007) 6968-6974. (Pubitemid 46847423)
39. Z. Bánki, L. Kacani, P. Rusert, M. Pruenster, D. Wilflingseder, B. Falkensammer, et al., Complement dependent trapping of infectious HIV in human lymphoid tissues, AIDS 19 (5) (2005) 481-486. (Pubitemid 40515851)
40. J.M. Prins, S. Jurriaans, R.M. van Praag, H. Blaak, R. van Rij, P.T. Schellekens, et al., Immuno-activation with anti-CD3 and recombinant human IL-2 in HIV-1-infected patients on potent antiretroviral therapy, AIDS 13 (1999) 2405-2410.
41. R.M. van Praag, J.M. Prins, M.T. Roos, P.T. Schellekens, I.J. Ten Berge, S.L. Yong, et al., OKT3 and IL-2 treatment for purging of the latent HIV-1 reservoir in vivo results in selective long-lasting CD4+ T cell depletion, J. Clin. Immunol. 21 (2001) 218-226. (Pubitemid 32434309)
42. L. Bhoopat, T. Rithaporn, S. Khunamornpong, T. Bhoopat, C. Taylor, P. Thorner, Sa.88. Cell reservoirs in lymph nodes infected with HIV-1 subtype E differ from subtype B: identi.cation by combined in situ polymerase chain reaction and immunohistochemistry, Clin. Immunol. 119 (Suppl. 1) (2006) S136.
43. L. Bhoopat, T.S. Rithaporn, S. Lekawanvijit, C.R. Taylor, A.M. Levine, T. Bhoopat, Different localization of dendritic cell reservoirs in human immunode.ciency virus-1 subtype B versus subtype E-infected lymph nodes, Appl. Immunohistochem. Mol. Morphol. 11 (2) (2003) 144-148. (Pubitemid 36749567)
44. L. Bhoopat, T.S. Rithaporn, S. Khunamornpong, T. Bhoopat, C.R. Taylor, P.S. Thorner, Cell reservoirs in lymph nodes infected with HIV-1 subtype E differ from subtype B: identi.cation by combined in situ polymerase chain reaction and immunohistochemistry, Mod. Pathol. 19 (2) (2006) 255-263. (Pubitemid 43117610)
45. M. Bull, G. Learn, I. Genowati, J. McKernan, J. Hitti, D. Lockhart, et al., Compartmentalization of HIV-1 within the female genital tract is due to monotypic and low-diversity variants not distinct viral populations, PLoS ONE 4 (9) (2009) e7122.
46. M. Poss, H.L. Martin, J.K. Kreiss, L. Granville, B. Chohan, P. Nyange, et al., Diversity in virus populations from genital secretions and peripheral blood from women recently infected with human immunodeficiency virus type 1, J. Virol. 69 (1995) 8118-8122.
47. M. Poss, A.G. Rodrigo, J.J. Gosink, G.H. Learn, D. de Vange Panteleeff, H.L. Martin Jr., et al., Evolution of envelope sequences from the genital tract and peripheral blood of women infected with clade A human immunodeficiency virus type 1, J. Virol. 72 (1998) 8240-8251. (Pubitemid 28421821)
48. A. Kovacs, S.S. Wasserman, D. Burns, D.J. Wright, J. Cohn, A. Landay, et al., Determinants of HIV-1 shedding in the genital tract of women, Lancet 358 (2001) 1593-1601. (Pubitemid 33101909)
49. K.S. Kemal, H. Burger, D. Mayers, K. Anastos, B. Foley, C. Kitchen, et al., HIV-1 drug resistance in variants from the female genital tract and plasma, J. Infect. Dis. 195 (2007) 535-545. (Pubitemid 46214396)
50. A. Si-Mohamed, M.D. Kazatchkine, I. Heard, C. Goujon, T. Prazuck, G. Aymard, et al., Selection of drug-resistant variants in the female genital tract of human immunodeficiency virus type 1-infected women receiving antiretroviral therapy, J. Infect. Dis. 182 (2000) 112-122. (Pubitemid 30497795)
51. L. Heath, A. Fox, J. McClure, K. Diem, A.B. van't Wout, H. Zhao, et al., Evidence for limited genetic compartmentalization of HIV-1 between lung and blood, PLoS ONE 4 (9) (2009) e6949.
52. M. Wayengera, Smart, nano-engineered drug (NRTI)-immune conjugates for targeting HIV within reservoirs, in: International Conference on AIDS. Int. Conf. AIDS, July 18-23, 2010; Track A: abstract no. TUPE0034.
53. E.A. Berger, I. Pastan, Immunotoxin complementation of HAART to deplete persisting HIV infected cell reservoirs, PLoS Pathog. 6 (6) (2010) e1000803.
54. L. Ylisastigui, J.J. Coull, V.C. Rucker, C. Melander, R.J. Bosch, S.J. Brodie, et al., Polyamides reveal a role for repression in latency within resting T cells of HIVinfected donors, J. Infect. Dis. 190 (2004) 1429-1437. (Pubitemid 39332182)
55. G. Lehrman, I.B. Hogue, S. Palmer, C. Jennings, C.A. Spina, A. Wiegand, et al., Depletion of latent HIV-1 infection in vivo: a proof-of-concept study, Lancet 366 (2005) 549-555. (Pubitemid 41140329)
56. J.D. Siliciano, J. Lai, M. Callender, E. Pitt, H. Zhang, J.B. Margolick, et al., Stability of the latent reservoir for HIV-1 in patients receiving valproic acid, J. Infect. Dis. 195 (2007) 833-836. (Pubitemid 46363928)
57. V.M. Richon, Y. Webb, R. Merger, T. Sheppard, B. Jursic, L. Ngo, et al., Second generation hybrid polar compounds are potent inducers of transformed cell differentiation, Proc. Natl. Acad. Sci. U.S.A. 93 (1996) 5705-5708. (Pubitemid 26191313)
58. J. Vlach, P.M. Pitha, Hexamethylene bisacetamide activates the human immunodeficiency virus type 1 provirus by an NF-kappa B-independent mechanism, J. Gen. Virol. 74 (Pt 11) (1993) 2401-2408. (Pubitemid 23332301)
59. B.A. Antoni, A.B. Rabson, A. Kinter, M. Bodkin, G. Poli, NF-kappa B dependent and -independent pathways of HIV activation in a chronically infected T cell line, Virology 202 (1994) 684-694.
60. X. Contreras, M. Barboric, T. Lenasi, B.M. Peterlin, HMBA releases P-TEFb from HEXIM1 and 7SK snRNA via PI3K/Akt and activates HIV transcription, PLoS Pathog. 3 (10) (2007) e146.
61. H.C. Yang, S. Xing, L. Shan, K. O'Connell, J. Dinoso, A. Shen, et al., Small-molecule screening using a human primary cell model of HIV latency identifies compounds that reverse latency without cellular activation, J. Clin. Invest. 119 (11) (2009) 3473-3486.
62. G.R. Pettit, Y. Kamano, C.L. Herald, M. Tozawa, Isolation and structure of Bryostatin-1, J. Am. Chem. Soc. 106 (1984) 6768-6771.
63. S.K. Davidson, S.W. Allen, G.E. Lim, C.M. Anderson, M.G. Haygood, Evidence for the biosynthesis of Bryostatins by the bacterial symbiont "Candidatus Endobugula sertula" of the bryozoan Bugula nertina, Appl. Environ. Microbiol. 67 (2001) 4531-4537. (Pubitemid 33646081)
64. R. Mehla, S. Bivalkar-Mehla, R. Zhang, I. Handy, H. Albrecht, S. Giri, et al., Bryostatin modulates latent HIV-1 infection via PKC andAMPKsignaling but inhibits acute infection in a receptor independent manner, PLoS ONE 5 (6) (2010) e11160.
65. M. Wayengera, Pre-integration gene slicing (PRINT-GSX) as an alternate or complimentary gene therapy modem to RNA interference, J. Appl. Biol. Sci. 1 (2) (2008) 56-63.
66. M. Wayengera, H. Kajumbula, W. Byarugaba, Frequency and site mapping of HIV-1/SIVcpz, HIV-2/SIVsmm and other SIV gene sequence cleavage by various bacteria restriction enzymes: precursors for a novel HIV inhibitory product, Afr. J. Biotechnol. 6 (10) (2007) 1225-1232.
67. M. Wayengera, H. Kajumbula, W. Byarugaba, Identification of restriction endonuclease with potential ability to cleave the HSV-2 genome: inherent potential for biosynthetic versus live microbicides, Theor. Biol. Med. Model 5 (2008) 18.
68. A. Levin, Z. Hayouka, A. Friedler, A. Loyter, Specific eradication of HIV-1 from infected cultured cells, AIDS Res. Ther. 7 (2010) 31.
69. D. Jochmans, M. Anders, I. Keuleers, L. Smeulders, H.G. Kraeusslich, G. Kraus, et al., Selective killing of human immunodeficiency virus infected cells by non-nucleoside reverse transcriptase inhibitor-induced activation of HIV protease, Retrovirology 7 (1) (2010) 89.
70. S.G. Deeks, J.M.McCune, Can HIV be cured with stem cell therapy? Nat. Biotechnol. 28 (2010) 807-810.
71. N. Holt, J. Wang, K. Kim, G. Friedman, X. Wang, V. Taupin, et al., Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo, Nat. Biotechnol. 28 (8) (2010) 839-847.